On October 15, 2020, the U.S. Food and Drug Administration (FDA) approved an expanded label for Keytruda
® (pembrolizumab) as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL). Keytruda is the first anti-PD-1 therapy approved for adult patients with relapsed or refractory cHL after frontline therapy.
Read Merck's press release and the FDA announcement.
Posted 10/15/2020